`Date Filed: March 8, 2017
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`WOCKHARDT BIO AG,
`Petitioner,
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner.
`
`________________
`
`Case IPR2016-01332
`Patent 8,822,438
`
`________________
`
`
`
`MOTION TO SEAL UNDER 37 C.F.R. §§ 42.14 AND 42.54
`
`
`
`
`
`
`
`
`
`
`IPR2016-01332
`Patent 8,822,438
`
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Patent Owner Janssen Oncology,
`
`Inc. (“Janssen”) respectfully submits this motion to seal the confidential version of
`
`Janssen’s Declaration of Christopher A. Vellturo, Ph.D., and Exhibits 2092, 2093,
`
`and 2118, which Janssen filed on March 8, 2016. The Parties have met and
`
`conferred and agreed to a modified version of the Board’s Default Protective Order
`
`contained in Appendix B of the Patent Trial Practice Guide. (See Ex. 2113).
`
`Pursuant to paragraph 4(A)(ii) of the Parties’ proposed Standing Protective Order,
`
`Patent Owner is also concurrently filing a non-confidential version of the
`
`Declaration of Christopher A. Vellturo, Ph.D. with the confidential portions
`
`redacted.
`
`I. Reasons for Sealing Certain Confidential Information
`
`Janssen’s Declaration of Christopher A. Vellturo, Ph.D. cites to material
`
`contained in Exhibits 2092 and 2093.
`
`Exhibits 2092 and 2093 contain non-public research summaries concerning
`
`the use of ZYTIGA®. These summaries include sensitive, non-public research in-
`
`formation and results of surveys of healthcare providers. Because Exhibits 2092,
`
`and 2093 contain Janssen’s non-public research, Janssen believes that good cause
`
`exists to seal Exhibits 2092 and 2093 in their entirety and the portions of the Dec-
`
`laration of Christopher A. Vellturo, Ph.D. disclosing confidential information from
`
`Exhibits 2092 and 2093.
`
`1
`
`
`
`
`IPR2016-01332
`Patent 8,822,438
`
`Exhibit 2118 contains non-public technical research and development in-
`
`formation. It describes highly sensitive information relating to the research and
`
`development of ZYTIGA®. Because Exhibit 2118 contains Janssen’s non-public
`
`research and development information, Janssen believes that good cause exists to
`
`seal Exhibit 2118 in its entirety.
`
`II. Certification of Non-Public Status
`
`With respect to Janssen’s Declaration of Christopher A. Vellturo, Ph.D. and
`
`Exhibits 2092, 2093 and 2118, Janssen’s undersigned counsel certifies that the
`
`information contained therein and sought to be sealed has not, to the best of their
`
`knowledge, been published or otherwise made public.
`
`III. Certification of Conference of the Parties Pursuant to 37 C.F.R. §
`42.54
`
`The Parties have conferred in good faith via email and agreed to the terms of
`
`a modified version of the Board’s Default Protective Order. See Ex. 2113.
`
`IV. Proposed Protective Order
`
`The Parties’ proposed Standing Protective Order submitted on March 8,
`
`2017 (see Ex. 2113) and to which the Parties have agreed to be bound in this
`
`matter, is a slightly modified version of the Board’s Default Protective Order. See
`
`Ex. 2114 (redline comparison of proposed and default protective orders).
`
`***
`
`2
`
`
`
`
`
`IPR2016-01332
`Patent 8,822,438
`
`For the foregoing reasons, Patent Owner respectfully requests that the Board
`
`enter an Order sealing the confidential versions of Janssen’s Declaration of
`
`Christopher A. Vellturo, Ph.D. and the entirety of Exhibits 2092, 2093, and 2118,
`
`and requiring the parties to abide by the Standing Protective Order (See Ex. 2113).
`
`
`
`Dated: March 8, 2017
`
`Respectfully Submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin (Reg. No. 28,598)
`delderkin@akingump.com
`Barbara L. Mullin (Reg. No. 38,250)
`bmullin@akingump.com
`Ruben H. Munoz (Reg. No. 66,998)
`rmunoz@akingump.com
`AKIN GUMP STRAUSS HAUER &
`FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`Tel: (215) 965-1200
`Fax: (215) 965-1210
`
`David T. Pritikin (pro hac vice)
`Bindu Donovan (pro hac vice)
`SIDLEY AUSTIN LLP
`787 Seventh Avenue
`New York, NY 10019
`Tel.: (212) 839-5300
`Fax: (212) 839-5599 ZytigaIPR-
`Team@sidley.com
`Counsel for Patent Owner
`
`
`3
`
`
`
`
`
`IPR2016-01332
`Patent 8,822,438
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing MOTION TO
`
`SEAL UNDER 37 C.F.R. §§ 42.14 AND 42.54 was served on counsel of record
`
`on March 8, 2017 by filing this document through the End-to-End System, as well
`
`as delivering a copy via electronic mail to counsel of record for the at the following
`
`addresses:
`
`Brandon M. White – bmwhite@perkinscoie.com
`Bryan D. Beel – bbeel@perkinscoie.com
`
`
`Respectfully submitted,
`
`
`
`Date: March 8, 2017
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`Janssen Oncology, Inc.
`
`
`112654981 v1
`
`4
`
`